Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Arturo Borzutzky, M.D.
Pontificia Universidad Catolica de Chile
Study Director - Carolina Iturriaga, R.N.
Pontificia Universidad Catolica de Chile
Principal Investigator - Diego García-Huidobro, M.D., Ph.D.
Pontificia Universidad Catolica de Chile
Principal Investigator - Eleanor Fish, Ph.D.
University Health Network, Toronto, Canada
Principal Investigator - Jose A Castro-Rodríguez, M.D., Ph.D.
Pontificia Universidad Catolica de Chile
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Red de Salud Uc Christus
Santiago, RM, Chile
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Sept 2021
- Primary completion
- 15 Apr 2022
- Completion
- 28 Jul 2022
- Last update posted
- 5 Aug 2022
- Registered enrollment
- 173
- Registry id
- NCT04988217
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.